论文部分内容阅读
目的:探讨ABC膜转运蛋白ABCG4在非小细胞肺癌(NSCLC)组织中的表达及其与临床病理因素和化疗药物敏感性的相关性。方法:免疫组化EnVinsion法、免疫荧光法检测AB-CG4在92例NSCLC组织中的表达,激光共聚焦显微镜观察其定位;MTT法检测相应癌组织对化疗药物的敏感性,分析其与ABCG4表达的相关性。结果:ABCG4阳性表达主要定位于胞膜和胞质,鳞癌阳性率为67.3%(33/49),腺癌为81.4%(35/43),两者差异有统计学意义,P=0.001;鳞癌Ⅱ期阳性率为41.7%(10/24),Ⅱ～Ⅲ期为92.0%(23/25),差异有统计学意义,P=0.000;腺癌中高分化阳性率为76.7%(23/30),低分化为92.3%(12/13),差异有统计学意义,P=0.033。环磷酰胺、吉西他滨、多柔比星、紫杉醇和顺铂在NSCLC组织中药物敏感性试验结果与其相应组织AB-CG4表达相关性检验,P均<0.05,rs均<-0.3,其中鳞癌中rs除紫杉醇外(-0.23)均<-0.3,而腺癌也均<-0.3。结论:ABCG4在NSCLC组织中高表达,表达的高低与病理分类、分级有关,并很可能与NSCLC化疗药物耐药有关。
OBJECTIVE: To investigate the expression of ABCG4, an ABC membrane transporter, in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological factors and chemosensitivity. Methods: The expression of AB-CG4 in 92 NSCLC tissues was detected by immunohistochemistry and immunofluorescence staining. The localization of AB-CG4 was detected by laser scanning confocal microscopy. The sensitivity of corresponding cancer tissues to chemotherapeutic drugs was detected by MTT assay. The expression of ABCG4 Relevance. Results: The positive expression rates of ABCG4 mainly localized in the membrane and cytoplasm. The positive rate of squamous cell carcinoma was 67.3% (33/49) and that of adenocarcinoma was 81.4% (35/43), the difference was statistically significant (P = 0.001). The positive rate of squamous cell carcinoma in stage Ⅱ was 41.7% (10/24), in stage Ⅱ ~ Ⅲ was 92.0% (23/25), the difference was statistically significant (P = 0.000). The positive rate of adenocarcinoma was 76.7% 30), poorly differentiated to 92.3% (12/13), the difference was statistically significant, P = 0.033. Cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin in NSCLC tissue drug sensitivity test results and its corresponding tissue AB-CG4 expression correlation test, P <0.05, rs <0. 3, of which squamous cell carcinoma rs except paclitaxel (-0.23) were <-0.3, while adenocarcinoma also <-0.3. Conclusion: ABCG4 is overexpressed in NSCLC tissues. The expression of ABCG4 is related to pathological classification and grading, and may be related to drug resistance of NSCLC chemotherapeutics.